SPRO

Spero Therapeutics' stock has increased significantly, with a 283.31% increase over the past year. The company reported its Q4 and full-year 2025 operating results on March 26, 2026, with a net income of $31.5 million for Q4 2025 and $8.6 million for the full year. GSK resubmitted the New Drug Application for tebipenem HBr to the FDA in December 2025, with a PDUFA date set for June 18, 2026. The company's cash is expected to fund operations into 2028, partly due to a milestone payment from GSK. There have been reports of insider selling and an increase in short interest. Analyst sentiment is mixed.